基于蛋白质空间结构的FGF分子改良和药效研究

基于蛋白质空间结构的FGF分子改良和药效研究数据集是由温州医科大学所建立的一个国家重点研发项目“蛋白激酶关联性代谢调控蛋白质机器的分离、鉴定与结构解析”的重要成果的原始数据集，涵盖支持基于FGF19-FGFR-βklotho三元复合物结构并结合二聚化阈值模型设计非促肿瘤型FGF19改构体，应用于二型糖尿病的临床前研究；基于结构分析提出并验收旁分泌-内分泌嵌合策略可显著改善FGF21的结构缺陷的相关研究成果的统计图表原始数据，蛋白质表达、结构表征图像原始数据和动物药理学原始数据。数据于2017年-2020年在温州医科大学采集。采集方案按对应实验具体要求的规范实施，设备为浙江省生物技术药物重点实验室和温州医科大学校级科研实验中心的生物医学相关仪器。The dataset for FGF molecule modification and pharmacodynamic research based on protein spatial structure is an original dataset developed by Wenzhou Medical University as a key achievement of the National Key R&D Program of China titled "Isolation, Identification and Structural Analysis of Protein Machines Regulated by Protein Kinase-associated Metabolism". It covers original data supporting the design of non-tumorigenic FGF19 variants for preclinical research of type 2 diabetes, which is based on the structure of FGF19-FGFR-βklotho ternary complex combined with the dimerization threshold model; original statistical chart data for research outcomes that proposed and validated the paracrine-endocrine chimeric strategy to significantly improve the structural defects of FGF21 via structural analysis; original data of protein expression and structural characterization images; and original animal pharmacology data. The dataset was collected at Wenzhou Medical University between 2017 and 2020. The collection protocols were implemented in compliance with the specifications required for corresponding experiments, using biomedical instruments from the Key Laboratory of Biotechnology Drugs of Zhejiang Province and the University-level Scientific Research Experimental Center of Wenzhou Medical University.

搜集汇总

背景与挑战

背景概述

该数据集是温州医科大学基于国家重点研发项目建立的原始数据集，聚焦于利用蛋白质空间结构进行FGF分子改良和药效研究。具体包括基于FGF19-FGFR-βklotho三元复合物结构设计非促肿瘤型FGF19改构体用于二型糖尿病临床前研究的数据，以及通过旁分泌-内分泌嵌合策略改善FGF21结构缺陷的统计图表、蛋白质表达和动物药理学原始数据。数据采集于2017年至2020年，涵盖基础药理学领域，总数据量为42.57MB，包含24个文件。